The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.
Mol Immunol
; 36(6): 387-95, 1999 Apr.
Article
em En
| MEDLINE
| ID: mdl-10444002
ABSTRACT
A mouse monoclonal antibody, anti-HM1.24 (IgG2a/kappa), binds to a surface antigen preferentially overexpressed on multiple myeloma (MM) cells, and exhibits potent antitumor cell activity against MM cells by antibody-dependent cell-mediated cytotoxicity (ADCC). To develop an antibody-based immunotherapy against MM, a humanized anti-HM1.24 antibody, in which all FRs correspond to naturally processed human FRs, has been successfully constructed with the aid of both the hybrid variable region and two-step design methods. This humanized anti-HM1.24 antibody (IgG1/kappa) is able to effectively induce ADCC against human myeloma KPMM2 and ARH77 cells in the presence of human PBMCs as effectively as a chimeric anti-HM1.24 antibody. The humanized anti-HM1.24 antibody, therefore, could be expected as a potent immunotherapeutic agent for MM patients.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Glicoproteínas de Membrana
/
Anticorpos
/
Citotoxicidade Celular Dependente de Anticorpos
/
Mieloma Múltiplo
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Mol Immunol
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Japão